What's new

Dr. Windi Muziasari, CEO of Resistomap, talks about how they are fighting the spread of antibiotic resistance genes by providing robust tools for monitoring.


Find out which types of SARS-CoV-2 vaccines are out there and how Takara Bio is joining the fight.


Researchers at Merck & Co., Inc. assess the use of rapid membrane processing for sample prep prior to PK studies in the drug development pipeline.


Takara Bio USA, Inc. collaborated with bioSyntagma, Inc. and their partners to develop and validate a new high-throughput method for COVID-19 testing, and are seeking an FDA Emergency Use Authorization.


Technology spotlight

Clone any insert, with any vector, at any site. In-Fusion seamless cloning technology makes it easy! Here’s how.

Constant genetic variation is the norm for influenza. Learn how a clever team of researchers overcame this challenge using In-Fusion Cloning for accurate, fast, and standardized subcloning—cutting the time from outbreak to vaccine: That's Good Science!